Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Tvardi Therapeutics (TVRD) FCF Margin (2016 - 2025)

Tvardi Therapeutics' FCF Margin history spans 13 years, with the latest figure at 182.64% for Q1 2025.

  • On a quarterly basis, FCF Margin rose 128289.0% to 182.64% in Q1 2025 year-over-year; TTM through Mar 2025 was 95.71%, a 62893.0% increase, with the full-year FY2024 number at 271.14%, up 17933.0% from a year prior.
  • FCF Margin hit 182.64% in Q1 2025 for Tvardi Therapeutics, up from 332.16% in the prior quarter.
  • Over the last five years, FCF Margin for TVRD hit a ceiling of 2363.87% in Q2 2024 and a floor of 1465.53% in Q1 2024.
  • Historically, FCF Margin has averaged 295.11% across 5 years, with a median of 313.53% in 2023.
  • The widest YoY moves for FCF Margin: up 265877bps in 2024, down -90400bps in 2024.
  • Tracing TVRD's FCF Margin over 5 years: stood at 151.64% in 2021, then tumbled by -375bps to 720.94% in 2022, then grew by 13bps to 630.43% in 2023, then surged by 47bps to 332.16% in 2024, then skyrocketed by 45bps to 182.64% in 2025.
  • Business Quant data shows FCF Margin for TVRD at 182.64% in Q1 2025, 332.16% in Q4 2024, and 260.37% in Q3 2024.